{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T01:42:11Z","timestamp":1648863731790},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"suppl 2","funder":[{"name":"Theravance Biopharma Antibiotics, Inc."},{"name":"Envision Scientific Solutions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2015,9,15]]},"DOI":"10.1093\/cid\/civ524","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T09:19:03Z","timestamp":1440667143000},"page":"S35-S37","source":"Crossref","is-referenced-by-count":1,"title":["Telavancin for the Treatment of Methicillin-Resistant<i>Staphylococcus aureus<\/i>Infections"],"prefix":"10.1093","volume":"61","author":[{"given":"Keith A.","family":"Rodvold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,8,27]]},"reference":[{"key":"2015082705480063000_61.suppl_2.S35.1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr437"},{"key":"2015082705480063000_61.suppl_2.S35.2","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf. Accessed 24 March 2015."},{"key":"2015082705480063000_61.suppl_2.S35.3","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ522","article-title":"Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions","author":"Wenzler","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480063000_61.suppl_2.S35.4","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480063000_61.suppl_2.S35.5","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01210-14"},{"key":"2015082705480063000_61.suppl_2.S35.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03172-14"},{"key":"2015082705480063000_61.suppl_2.S35.7","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ523","article-title":"Evolving resistance among gram-positive pathogens","author":"Munita","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480063000_61.suppl_2.S35.8","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ528","article-title":"Skin and soft tissue infections: a critical review and the role of telavancin in their treatment","author":"Cardona","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480063000_61.suppl_2.S35.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.862-867.2006"},{"key":"2015082705480063000_61.suppl_2.S35.10","doi-asserted-by":"publisher","DOI":"10.1086\/429914"},{"key":"2015082705480063000_61.suppl_2.S35.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2008.05.012"},{"key":"2015082705480063000_61.suppl_2.S35.12","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"2015082705480063000_61.suppl_2.S35.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"},{"key":"2015082705480063000_61.suppl_2.S35.14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit614"},{"key":"2015082705480063000_61.suppl_2.S35.15","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ535","article-title":"The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia","author":"Sandrock","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480063000_61.suppl_2.S35.16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"2015082705480063000_61.suppl_2.S35.17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02330-13"},{"key":"2015082705480063000_61.suppl_2.S35.18","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ536","article-title":"Telavancin hospital-acquired pneumonia trials: impact of gram-negative infections and inadequate gram-negative coverage on clinical efficacy and all-cause mortality","author":"Lacy","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_2\/S35\/1114530\/civ524.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T20:24:00Z","timestamp":1503433440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/civ524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,27]]},"references-count":18,"journal-issue":{"issue":"suppl 2","published-online":{"date-parts":[[2015,8,27]]},"published-print":{"date-parts":[[2015,9,15]]}},"alternative-id":["10.1093\/cid\/civ524"],"URL":"https:\/\/doi.org\/10.1093\/cid\/civ524","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,27]]}}}